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Alpha interferon (aIFN) therapy is known to induce thyroid autoimmunity in up to 40% of patients.
The mechanism is unknown, but Th1 switching has been hypothesized. The aim of our study was to
examine whether aIFN accelerated the development of thyroiditis in genetically susceptible mice.
We took advantage of NOD-H2h4, a genetically susceptible animal model, which develops thyroiditis
whenfedahighiodinediet.SixtoeightweekoldmaleNODH2h4micewereinjectedwithmouseaIFN
(200 units) or with saline three times a week for 8 weeks. All mice drank iodinated water (0.15%). Mice
were sacriﬁced after 8 weeks of injection. Their thyroids were examined for histology and blood was
testedforantithyroglobulinantibodylevels.T4andglucoselevelswerealsoassessed.IntheIFN-injected
group, 6/13 (46.2%) developed thyroiditis and/or thyroid antibodies while in the saline-injected
group, only 4/13 (30.8%) developed thyroiditis and/or thyroid antibodies ðp ¼ 0:4Þ: The grade of
thyroiditis was not different amongst the two groups. None of the mice developed clinical thyroiditis or
diabetes mellitus. Our results showed that aIFN treatment did not accelerate thyroiditis in this mouse
model. This may imply that aIFN induces thyroiditis in a non-genetically dependent manner, and this
wouldnotbedetectedinageneticallysusceptiblemousemodeliftheeffectweresmall.Alternatively,itis
possible that aIFN did not induce thyroiditis in mice because, unlike in humans, in mice aIFN does not
induce Th1 switching.
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INTRODUCTION
Alpha interferon (aIFN) treatment for various medical
conditions is known to induce thyroid autoimmunity in
up to 40% of patients. The association between aIFN
treatment and autoimmune thyroiditis was reported as
early as 1986 by Burman et al. (1986), who studied
patients receiving aIFN for carcinoid tumors.
The association is most recognized in patients
with hepatitis C (Watanabe et al., 1994), although
it has been noted to occur in several other conditions
treated by aIFN including breast cancer, carcinoid and
hematologic malignancies (Fentiman et al., 1988;
Ronnblom et al., 1991a,b; Gisslinger et al.,1 9 9 2 ;
Silvestri et al., 1994; Watanabe et al., 1994).
The thyroid diseases associated with aIFN therapy
include both autoimmune hyperthyroidism and
hypothyroidism (Koh et al., 1997). In up to 40% of
cases, thyroid dysfunction persists after discontinuation
of the aIFN therapy (Koh et al., 1997).
Factors that predispose patients to the development of
aIFN-induced thyroiditis include hepatitis C infection,
positive pre-treatment antithyroid antibodies, dose and
duration of aIFN therapy, genetic factors, stress, dietary
iodine intake, female gender, pregnancy and HLA-A2
in the Japanese population (Preziati et al., 1995;
Roti et al., 1996; Custro et al., 1997; Koh et al., 1997;
Minelli et al., 1997; Fernandez-Soto et al., 1998;
Dumoulin et al., 1999; Kakizaki et al., 1999, 2000).
The mechanisms by which aIFN induces thyroid
autoimmunity are unclear.
We hypothesized that aIFN accelerates subclinical
thyroiditis by immune modulation in genetically predis-
posed individuals. In order to examine this hypothesis, we
took advantage of the NOD H2h4 mouse model, a model
in which the mice are genetically prone to develop
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(Rasoolyetal.,1996;Braley-Mullenetal.,1999).Weused
the NOD H2h4 mouse model to examine the effects of
aIFN on animals genetically susceptible to thyroiditis.
MATERIALS AND METHODS
Animal Protocol
Mouse interferon alpha was obtained from PBL
Biomedical Laboratories (New Brunswick, NJ). Six to
eight week old NOD H2h4 male mice were purchased
from Taconic Farms (Germantown, NY). Male mice
were used in our experiments since previous studies
(Rasooly et al., 1996; Braley-Mullen et al., 1999) and our
own experiments revealed that male mice are more prone
to thyroiditis in this model (data not shown). Thirteen
mice were injected intra peritoneally (i.p.) with aIFN
(200 units, 0.4 cc) three times a week for eight weeks.
As controls, 13 mice were injected with saline (0.4 cc)
three times a week for eight weeks. After eight weeks of
injections, mice were sacriﬁced, 1ml of blood was drawn,
and their thyroids were removed. All these 26 mice were
given 0.15% iodinated drinking water [Sodium Iodide,
Sigma Chemical Company (St. Louis, MO)]. Additional
14 mice (6 injected with saline and 8 injected with aIFN)
received regular water without iodine supplementation.
Measurement of Murine Tg (mTg) Antibodies
Serum was analyzed for mTg antibodies by an ELISA
assay as previously described (Imaizumi et al., 2001).
Brieﬂy, 96 well-plates (Immulon 1, Dynex Technologies
Inc., Pittsburgh, PA) were coated with mouse thyro-
globulin (0.1mcg thyroglobulin/well diluted in
Carbonate/Bicarbonate Buffer, pH 9.6) and incubated
overnight at 48C. The plates were washed with 0.05%
PBS-Tween and nonspeciﬁc binding was blocked for
30min with 3% BSA-PBS/Tween. After washing, the sera
were diluted 1:100 in 0.5% BSA/PBS and added to the
plates for 2h at room temperature. Plates were washed
again 6 times and alkaline phosphatase conjugated anti
mouse IgG (Sigma Diagnostics, St. Louis, MO) was added
for 30min. Plates were washed 4 times and then
developed using p-nitrophenyl phosphate as substrate.
Absorbance was read at 405nm. Samples were considered
positive if the OD was 2 standard deviation (SD) above the
average OD for controls.
Thyroid Histology
Mice thyroids were ﬁxed in 10% formalin and stained by
hematoxylin and eosin. The severity of thyroiditis was
graded on a scale from þ1t oþ4.0 as follows: þ1, small
focal areas of lymphocytic cells; þ2, focal collection of
lymphocytic cells with some follicular destruction; þ3,
diffuse lymphocytic inﬁltration of thyroid follicles
involving approximately 40% or less of the thyroid and
þ4, .40% lymphocytic inﬁltration of thyroid follicles
(Fig. 1; Imaizumi et al., 2001).
Measurement of Total Thyroxine (T4) and Glucose
Levels
T4 was measured by radioimmunoassay using the
neonatal T4 Coat-A-Count kit (Diagnostics Products
Corporation, Los Angeles, CA). Glucose levels were
measured using the One Touch Proﬁle Glucometer
(Lifescan Inc., Milpitas, CA).
FIGURE 1 Histological grading of thyroiditis. After eight weeks
injections, mice were sacriﬁced. Thyroids were removed and ﬁxed and
stained by H&E. (A) Normal mouse thyroid, (B) Grade 1 thyroiditis,
(C) Grade 2 thyroiditis. None of our mice developed thyroiditis with
severity . þ2.
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Data were analyzed using Student’s, Chi-Square and
Fisher Exact tests. Probability values less than 0.05 were
considered signiﬁcant.
RESULTS
Effects of Iodine on Development of Thyroiditis
None of the 14 mice that did not receive iodine
supplementation (6 injected with saline and 8 injected
with aIFN) developed thyroiditis. In contrast, 10/26
(38.5%) of the mice that received iodine supplementation
developed thyroiditis ðp ¼ 0:007Þ:
Autoantibody Levels in aIFN-injected Mice and
Controls
Positive thyroglobulin antibodies were detected in 3/13
(23%) of the mice injected with aIFN compared to 0% of
the control mice injected with saline ðp ¼ 0:07Þ:
Thyroid Histology in aIFN-injected Mice and Controls
Thyroid inﬁltration was detected in 5/13 (38.5%) of the
aIFN-injected mice and 4/13 (30.8%) in the control mice
(Table I). The grade of thyroiditis was not different
between the aIFN-injected versus controls. When we used
positive thyroid antibodies and/or positive histology to
deﬁne thyroiditis, 6/13 (46.2%) of the mice injected with
aIFN developed thyroiditis compared to 4/13 (30.8%) in
the control mice (Table I). This difference did not reach
statistical signiﬁcance ðp ¼ 0:4Þ:
Clinical Disease in aIFN-injected Mice and Controls
None of the mice developed evidence of clinical thyroid
dysfunction and/or diabetes mellitus. There were no
signiﬁcant differences in the T4 levels between the
4 groups mice (Fig. 2). Moreover, the levels of T4 were
similar in the mice that developed thyroiditis and those
that did not (average Total T4 level ¼ 4.24 in mice that
developed thyroiditis vs. 4.19 in mice that did not develop
thyroiditis) (Fig. 2).
Since it has been previously reported that
insulitis develops in 20–30% of NODH2h4 mice
(Braley-Mullen et al., 1999), we also tested blood
glucose levels. There were no signiﬁcant differences in
the glucose levels between mice that developed thyroiditis
and those that did not in both groups (average glucose
level ¼ 174 vs. 165.2) (Fig. 3).
DISCUSSION
Interferons are cytokines that are involved in immune
modulation, possessing both antiviral and antitumoral
activity. Interferons are grouped into Types I and II. Type I
interferons are acid stable and include alpha, beta and
omega subtypes. Type II inteferons are acid labile and
include the gamma subtype (Walter et al., 1998). aIFN
ﬁrst became available for use in humans in the form
of leukocyte-derived interferon in the mid 1970’s.
Subsequently, in 1986, recombinant aIFN became
available for clinical use. Since that time, recombinant
interferons have been used to treat a wide spectrum of
medical conditions, including hepatitis, and several
cancers (Walter et al., 1998).
Interferons were shown to induce and/or exacerbate
several autoimmune diseases, including autoimmune
thyroiditis, autoimmune hepatitis, rheumatoid and
lupus like diseases, and autoimmune diabetes mellitus.
Interestingly, thyroid disease is the most prevalent
autoimmune disease exacerbated or induced by aIFN
(Dumoulin et al., 1999). It is unclear whether this reﬂects
the higher prevalence of thyroid autoimmunity in the
general population or a thyroid speciﬁc effect of
interferon.
Our hypothesis was that aIFN accelerates thyroiditis in
genetically prone individuals. Evidence supporting our
hypothesis is that most of the risk factors for aIFNinduced
thyroiditis are genetic (e.g. positive pre-treatment
antithyroid antibodies, and female gender) (Preziati
et al., 1995; Roti et al., 1996; Custro et al., 1997; Minelli
et al., 1997; Tunbridge et al., 1977; Koh et al., 1997;
Fernandez-Soto et al., 1998; Kakizaki et al., 1999;
Dumoulin et al., 1999; Kakizaki et al., 2000). In order to
TABLE I Thyroiditis and thyroglobulin antibody frequency in mice
injected with saline and aIFN
Saline injection
(n=13)
aIFN injection
(n=13)
P
value
Positive histology
for thyroiditis
4 (31%) 5 (39%) NS*
Thyroiditis on histology
and/or elevated Tg-Ab’s
4 (31%) 6 (46%) NS
*NS, not signiﬁcant.
FIGURE 2 T4 levels in mice injected with IFN or saline and fed with
water or NaI. There were no signiﬁcant differences in the T4 levels of
mice that developed thyroiditis and those that did not in both groups
(average Total T4 level ¼ 4.24 vs. 4.19).
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susceptible to thyroiditis.
Our study revealed that aIFN did not accelerate
thyroiditis in this thyroiditis-prone mouse model. Thus
our study does not support an accelerating effect of aIFN
on autoimmune thyroid disease development atleast inour
mouse model. Therefore, it is possible that aIFN induces
thyroiditis de novo and does not accelerate disease
development in genetically predisposed individuals. Such
a de novo effect would not be detected in our mice, which
are already prone for thyroiditis, especially if this is a mild
effect. Alternatively, it is possible that aIFN did accelerate
thyroiditis development in the NOD H2h4 mice but that
the effect was too small to be detected in our experiments.
Our studies showed a higher frequency of thyroiditis in the
aIFNinjectedgroupversusthecontrols(48.2%and30.8%,
respectively), however this difference did not reach
statistical signiﬁcance. Power calculations show that at
least 80 mice per group would have been required to reach
statistical signiﬁcance for the difference that we observed.
Additionally, there is some variability in the incidence of
thyroiditisinthismousemodel, which may haveinterfered
with detection of a small effect (Rasooly et al., 1996;
Braley-Mullen et al., 1999). Another explanation for the
lack of an effect of aIFN in the mice may be due to its
inability to induce Th1 switching in mice. Unlike in
humans, aIFN does not induce Th1 switching in mice
because of its failure to activate the signal transducer and
activator of transcription 4 (Stat4) (Farrar and Murphy,
2000). Some authors have suggested that aIFN accelerates
human thyroiditis by inducing Th1 switching (Farrar and
Murphy, 2000) and, if this is indeed the case, the lack of
aIFN-induced thyroiditis in our mice may reﬂect the
absence of aIFN-induced Th1 differentiation and activa-
tion of Stat4 in mice. However, it is unclear whether Th1
switching can explain aIFN-induced thyroiditis as 40% of
patientsdevelopGraves’disease,generallybelievedtobea
Th2 mediated disease (Davies, 2000).
In summary, aIFN did not accelerate thyroiditis in this
mouse model. However, minor aIFN effects cannot be
excluded. Additional studies are needed to examine this
possibility.
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